Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Astria Therapeutics Inc

Healthcare US ATXS

NoneUSD
0.00(0%)

Last update at 2026-04-23T21:02:15.055519Z

Day Range

--
LowHigh

52 Week Range

3.695873.65
LowHigh

Fundamentals

  • Previous Close 5873.65
  • Market Cap718.13M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-32.38000M
  • Revenue TTM0.71M
  • Revenue Per Share TTM0.01
  • Gross Profit TTM 0.71M
  • Diluted EPS TTM-2.14

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -94.26000M -72.89100M -51.83400M -194.91200M -37.30000M
Minority interest - - - - -
Net income -94.26000M -72.89100M -50.16500M -30.17300M -37.06400M
Selling general administrative 33.95M 25.70M 19.24M 14.81M 11.85M
Selling and marketing expenses 1.30M 0.60M - - -
Gross profit - - - - -
Reconciled depreciation - - - - -
Ebit -111.55800M -67.83100M -53.50300M -194.97600M -37.03500M
Ebitda -111.55800M -83.03000M -53.50300M 134.26M -37.43500M
Depreciation and amortization - -15.19900M 1.67M 329.23M -
Non operating income net other - - 1.67M - -
Operating income -111.55800M -83.03000M -53.50300M -194.97600M -37.43500M
Other operating expenses 111.56M 83.03M 53.50M 30.36M 37.44M
Interest expense - - 1.67M 0.06M 0.24M
Tax provision - - - - -
Interest income 17.36M 10.20M 1.72M 0.12M 0.24M
Net interest income 17.36M 10.20M 1.72M 0.12M 0.24M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - 0.02M -1.66900M -164.73900M -0.23600M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 111.56M 83.03M 53.50M 30.36M 37.44M
Cost of revenue - - - - -
Total other income expense net 17.30M 10.14M 1.67M 0.06M 0.14M
Discontinued operations - - - - -
Net income from continuing ops -94.26000M -72.89100M -51.83400M -194.91200M -37.30000M
Net income applicable to common shares - - -51.83400M -219.34900M -37.30000M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 342.36M 254.67M 230.63M 127.51M 47.46M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 6.51M 4.25M 1.25M 1.57M 1.40M
Total liab 23.10M 11.55M 9.42M 5.20M 6.79M
Total stockholder equity 319.26M 243.12M 221.22M 122.31M 40.67M
Deferred long term liab - - - - -
Other current liab 13.43M 9.71M -0.78800M 3.28M 4.20M
Common stock 0.06M 0.04M 0.03M 0.01M 0.02M
Capital stock 95.38M 95.36M 96.43M 96.41M 0.02M
Retained earnings -674.79400M -580.53400M -507.64300M -455.80900M -260.89700M
Other liab - - - - -
Good will - - - - -
Other assets - 0.00000M 3.25M 0.04M 0.17M
Cash 59.82M 175.69M 20.52M 86.51M 24.93M
Cash and equivalents - - - - -
Total current liabilities 19.13M 11.55M 0.58M 5.20M 6.39M
Current deferred revenue - - - - -
Net debt -54.46700M -175.36400M -19.58600M -86.14300M -23.88400M
Short term debt 1.38M 0.33M 0.58M 0.36M 0.65M
Short long term debt - - - - -
Short long term debt total 5.35M 0.33M 0.94M 0.36M 1.05M
Other stockholder equity 898.51M 823.61M 632.51M 481.71M 301.55M
Property plant equipment - - 0.95M 0.39M 0.97M
Total current assets 334.64M 250.94M 226.44M 127.08M 46.33M
Long term investments - - - - -
Net tangible assets - - 124.82M 25.91M 40.67M
Short term investments 268.31M 71.00M 205.91M 39.00M 20.00M
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 4.32M 1.51M 0.79M 1.56M 1.54M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.16M -95.32400M -0.07900M - -
Additional paid in capital - - - - -
Common stock total equity - - 0.03M - 0.02M
Preferred stock total equity - - 96.40M - -
Retained earnings total equity - - -507.64300M - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 2.61M 3.36M 3.25M 0.04M 0.17M
Deferred long term asset charges - - - - -
Non current assets total 7.72M 3.72M 4.20M 0.44M 1.13M
Capital lease obligations 5.35M 0.33M 0.94M 0.36M 1.05M
Long term debt total - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments -191.86300M 135.05M -167.03800M -19.00000M 6.33M
Change to liabilities - - 3.64M -1.96500M 0.35M
Total cashflows from investing activities -191.86300M 135.05M -167.12900M -12.55500M 6.30M
Net borrowings - - - - -
Total cash from financing activities 157.20M 88.40M 144.72M 104.28M 40.86M
Change to operating activities - - - -1.34000M 3.02M
Net income -94.26000M -72.89100M -51.83400M -194.91200M -37.30000M
Change in cash -115.87300M 155.00M -65.94100M 61.58M 14.68M
Begin period cash flow 175.69M 20.69M 86.63M 25.05M 10.38M
End period cash flow 59.82M 175.69M 20.69M 86.63M 25.05M
Total cash from operating activities -81.21200M -68.44500M -43.53300M -30.15100M -32.48500M
Issuance of capital stock 152.42M 87.98M 144.64M 104.26M 40.83M
Depreciation - - - - -
Other cashflows from investing activities - - - - -
Dividends paid - - - 24.44M -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - 107.73M - -
Other cashflows from financing activities 4.79M 0.42M 0.08M 24.46M 0.03M
Change to netincome - - 4.67M 168.07M 1.45M
Capital expenditures 0.33M 0.03M 0.09M 0.02M 0.03M
Change receivables - - - - -
Cash flows other operating - - -0.00600M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - -65.94100M - -
Change in working capital 4.54M -2.41300M 2.65M -3.30500M 3.37M
Stock based compensation 13.04M 6.31M 4.55M 3.36M -
Other non cash items -4.53700M 0.55M 1.10M 164.70M 1.45M
Free cash flow -81.53700M -68.47000M -43.62400M -30.17200M -32.51800M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ATXS
Astria Therapeutics Inc		 - -% - - - 1017.18 5.21 835.96 -7.5695
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts. As of January 23, 2026, Astria Therapeutics, Inc. operates as a subsidiary of BioCryst Pharmaceuticals, Inc.

Astria Therapeutics Inc

22 Boston Wharf Road, Boston, MA, United States, 02210

Key Executives

Name Title Year Born
Ms. Jill C. Milne Ph.D. Co-Founder, CEO, Pres & Director 1968
Mr. Noah Clauser CPA Chief Financial Officer 1974
Dr. Andrew J. Nichols Ph.D. Chief Scientific Officer 1961
Mr. Benjamin S. Harshbarger J.D. Chief Legal Officer 1969
Ms. Keri McGrail Sr. VP of HR NA
Ms. Andrea L. Matthews Sr. VP of Corp. Affairs NA
Mr. Andrew A. Komjathy Chief Commercial Officer 1964
Dr. Anthony Christopher Stevens M.D. Interim Chief Medical Officer 1959
Dr. Christopher J. Morabito M.D. Chief Medical Officer 1970
Ms. Jill C. Milne Ph.D. Co-Founder, CEO, President & Director 1968

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions